0001213900-24-097866.txt : 20241114 0001213900-24-097866.hdr.sgml : 20241114 20241114090003 ACCESSION NUMBER: 0001213900-24-097866 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20241114 DATE AS OF CHANGE: 20241114 EFFECTIVENESS DATE: 20241114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cadrenal Therapeutics, Inc. CENTRAL INDEX KEY: 0001937993 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880860746 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-529374 FILM NUMBER: 241457544 BUSINESS ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 300 CITY: PONTE VEDRA STATE: FL ZIP: 32082 BUSINESS PHONE: 904-300-0701 MAIL ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 300 CITY: PONTE VEDRA STATE: FL ZIP: 32082 D 1 primary_doc.xml X0708 D LIVE 0001937993 Cadrenal Therapeutics, Inc. 822 A1A NORTH, SUITE 306 PONTE VEDRA FL FLORIDA 32082 (904) 300-0701 DELAWARE None None Corporation true 2022 Quang Pham 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Director Matthew Szot 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Douglas W. Losordo 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Jeff Cole 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Steven Zelenkofske 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Director Glynn Wilson 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Director Robert Lisicki 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Director John R. Murphy 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Director Biotechnology Decline to Disclose 06b false 2024-11-01 false true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue New York NY NEW YORK 10022 NY NEW YORK false 9428594 9428594 0 The total offering amount reflects the total gross proceeds to be received assuming cash exercise of all warrants issued in the private placement. true 0 5 468000 true 0 In connection with the offering, the placement agent received a 7.0% cash fee, 1.0% management fee, non-accountable expenses, warrants, accountable expenses and clearing fee 0 true While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Cadrenal Therapeutics, Inc. /s/ Quang Pham Quang Pham Chief Executive Officer 2024-11-14